← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	AGTC 26 DELISTED Applied Genetic Technologies Corporation AGTC	90	-5	-5%	$108M
27	27 Atara Biotherapeutics ATRA $93.1M	86	+10	+13%	$330M
28	28 Arrowhead Research ARWR $8.31B	85	-12	-12%	$39.5M
29	29 Editas Medicine EDIT $372M	84	+9	+12%	$381M
30	30 DELISTED Adverum Biotechnologies ADVM	83	+7	+9%	$43.8M
31	31 Standard BioTools LAB $254M	83	-15	-15%	$196M
32	32 Rocket Pharmaceuticals RCKT $251M	82	+4	+5%	$109M
33	BLCM 33 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	80	+10	+14%	$266M
34	ATHX 34 DELISTED Athersys, Inc. Common Stock ATHX	79	+6	+8%	$23.1M
35	35 Regenxbio RGNX $461M	78	+7	+10%	$339M
36	36 Veracyte VCYT $3.62B	74	+19	+35%	$160M
37	37 Intellia Therapeutics NTLA $1.63B	70	+5	+8%	$241M
38	38 Invesco Biotechnology & Genome ETF PBE $430M	68	0	0%	$47.5M
39	NVTA 39 DELISTED Invitae Corporation NVTA	64	+13	+25%	$214M
40	40 Voyager Therapeutics VYGR $128M	56	+3	+6%	$140M
41	41 Arbutus Biopharma ABUS $842M	55	+7	+15%	$88.8M
42	42 Abeona Therapeutics ABEO $272M	54	+15	+38%	$72M
43	43 Lakefront Biotherapeutics American Depositary Shares LKFT $1.97B	52	+4	+8%	$642M
44	44 Fortress Biotech FBIO $64.7M	51	0	0%	$18.1M
45	45 uniQure QURE $1.52B	51	+2	+4%	$42.7M
46	46 Wave Life Sciences WVE $619M	51	+5	+11%	$388M
47	47 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	49	+2	+4%	$6.65M
48	48 Neurogene NGNE $487M	49	+3	+7%	$386M
49	49 Vericel Corp VCEL $2.13B	46	+1	+2%	$28.4M
50	50 Cartesian Therapeutics RNAC $202M	43	+14	+48%	$140M